Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
J Hematol ; 6(4): 90-95, 2017 Oct.
Article in English | MEDLINE | ID: mdl-32300400

ABSTRACT

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous and highly aggressive subtype of non-Hodgkin's lymphoma. It commonly presents as rapidly-growing, painless lymphadenopathy (LAD). DLBCL presenting in leukemic-phase is rare, with fewer than 40 cases published. Chemotherapy remains the standard approach, although selecting the correct regimen has become more perplexing in patients with CDKN2A mutations. Patients with MLL- and CDKN2A-positive DLBCL may benefit from therapy with a dose-adjusted regimen of rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-R-EPOCH) compared to traditional rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP). Herein, we report a case of leukemic-phase DLBCL presenting as a cutaneous eruption of the bilateral lower extremities, which has not been previously reported in the literature.

2.
R I Med J (2013) ; 99(4): 16-9, 2016 Apr 01.
Article in English | MEDLINE | ID: mdl-27035134

ABSTRACT

There is growing evidence that obesity increases the risk of certain cancers and cancer mortality. As obesity rates are projected to rise over the next decade, associated cancer morbidity and mortality present a significant public health concern. This is particularly striking in the state of Rhode Island, where nearly a third of the population is obese. Interventions such as taxation of obesity-associated foods or insurance incentive programs promoting positive health behaviors could decrease obesity-associated cancer incidence and mortality over time. Public health programs could be deployed at both the local and national levels. We provide a background on obesity-related cancer, discuss existing evidence to support these ideas, and make recommendations regarding individual and societal factors when considering public policy, health-care delivery, taxation structure, and insurance.


Subject(s)
Neoplasms/epidemiology , Obesity/epidemiology , Adult , Carcinogenesis , Cost Savings , Delivery of Health Care/economics , Health Policy/economics , Humans , Insurance, Health/economics , Neoplasms/economics , Neoplasms/etiology , Obesity/complications , Obesity/economics , Patient Protection and Affordable Care Act/economics , Rhode Island/epidemiology , Risk Factors , Taxes/economics
3.
Clin Chem ; 62(5): 773-80, 2016 05.
Article in English | MEDLINE | ID: mdl-26988581

ABSTRACT

BACKGROUND: We implemented oral fluid (OF) as an alternative specimen type to urine for detection of cocaine (COC) and opiate abuse in outpatient addiction medicine clinics. METHODS: We implemented a 2-µg/L limit of quantification OF LC-MS/MS assay and compiled and reviewed all findings from a 22-month collection period for COC, benzoylecgonine (BZE), codeine (COD), 6-acetylmorphine (MAM), and morphine (MOR). We also compared the results of our clinical samples at different OF cutoffs and analytes specified in the new 2015 SAMHSA OF guidelines. RESULTS: Of 3608 OF samples, COC and BZE were positive in 593 and 508, respectively. COC or BZE was positive in 662 samples. Importantly and unexpectedly, 154 samples were COC positive and BZE negative, with 125 having COC 2.0-7.9 µg/L. A simulation with the new guideline cutoffs confirmed 65% (430 of 662) of all COC- or BZE-positive data set samples. Similarly, the new guidelines confirmed 44% (263 of 603) of data set samples positive for MOR or COD. Simulation found that the new, lower MAM guideline cutoffs detected 89% of the 382 MAM-positive samples in the data set, 104 of which the new guidelines had identified as negative for MOR and COD. CONCLUSIONS: COC (not BZE) is the dominant low-concentration OF analyte in an addiction medicine setting. This information will aid OF test interpretation. It also illustrates the importance of the 2015 guideline's new immunoassay cross-reactivity requirements and the likely improvement in detection of heroin use stemming from the new, lower MAM cutoffs.


Subject(s)
Cocaine/analysis , Heroin/analysis , Substance Abuse Detection , Substance-Related Disorders/diagnosis , United States Substance Abuse and Mental Health Services Administration , Administration, Oral , Adult , Chromatography, Liquid , Cocaine/administration & dosage , Female , Heroin/administration & dosage , Humans , Male , Tandem Mass Spectrometry , United States
4.
Am J Clin Oncol ; 39(6): 619-622, 2016 12.
Article in English | MEDLINE | ID: mdl-26523444

ABSTRACT

BACKGROUND: The Brown University Oncology Research Group performed a phase I study to remove irinotecan from FOLFIRINOX (5-fluorouracil, oxaliplatin, irinotecan, and leucovorin) and substitute nab-paclitaxel. METHODS: Patients with newly diagnosed advanced pancreatic adenocarcinoma were eligible. Patients received oxaliplatin 85 mg/m, leucovorin 400 mg/m, and 5-fluorouracil 2400 mg/m with 3 dose levels of nab-paclitaxel (125, 150, and 175 mg/m) every 2 weeks. Dose-limiting toxicities were assessed in the first 2 cycles of treatment. The final dose level was expanded to assess cumulative neurotoxicity. RESULTS: Thirty-five patients were entered; 24 with metastatic and 11 with locally advanced pancreatic cancer. The maximum tolerated dose of nab-paclitaxel was 150 mg/m every 2 weeks with FOLFOX. Cumulative neuropathy was the most important toxicity. Grade 3 neuropathy developed in 2 of the first 6 patients at 10 and 11 cycles of FOLFOX-A. Following an amendment to reduce oxaliplatin to 65 mg/m if grade 2 neuropathy developed, no additional patients developed grade 3 neurotoxicity. Twenty-one of 35 patients (60%) had a partial response. The median survival for patients with metastatic disease was 15 months. CONCLUSIONS: The maximum tolerated dose of nab-paclitaxel is 150 mg/m every 2 weeks with FOLFOX. The regimen of FOLFOX-A represents a promising treatment for pancreatic cancer.


Subject(s)
Adenocarcinoma/drug therapy , Adenocarcinoma/pathology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Pancreatic Neoplasms/drug therapy , Pancreatic Neoplasms/pathology , Adenocarcinoma/mortality , Adult , Aged , Albumins/administration & dosage , Albumins/adverse effects , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Disease-Free Survival , Dose-Response Relationship, Drug , Drug Administration Schedule , Fluorouracil/administration & dosage , Fluorouracil/adverse effects , Fluorouracil/therapeutic use , Humans , Infusions, Intravenous , Kaplan-Meier Estimate , Leucovorin/administration & dosage , Leucovorin/adverse effects , Leucovorin/therapeutic use , Maximum Tolerated Dose , Middle Aged , Neoplasm Invasiveness/pathology , Neoplasm Staging , Organoplatinum Compounds/administration & dosage , Organoplatinum Compounds/adverse effects , Organoplatinum Compounds/therapeutic use , Oxaliplatin , Paclitaxel/administration & dosage , Paclitaxel/adverse effects , Pancreatic Neoplasms/mortality , Prognosis , Prospective Studies , Risk Assessment , Survival Analysis , Treatment Outcome
5.
Onco Targets Ther ; 7: 333-42, 2014.
Article in English | MEDLINE | ID: mdl-24591840

ABSTRACT

In the last decade, the advent of biological targeted therapies has revolutionized the management of several types of cancer, especially in the realm of hematologic malignancies. One of these pathways, and the center of this review, is the phosphatidylinositol-3-kinase (PI3K) pathway. The PI3K pathway seems to play an important role in the pathogenesis and survival advantage in hematologic malignancies, such as leukemia, lymphoma, and myeloma. The objectives of the present review, hence, are to describe the current knowledge on the PI3K pathway and its isoforms, and to summarize preclinical and clinical studies using PI3K inhibitors, focusing on the advances made in hematologic malignancies.

6.
Br J Haematol ; 165(3): 300-15, 2014 May.
Article in English | MEDLINE | ID: mdl-24533596

ABSTRACT

The association between viruses and lymphomas has long been recognized; however, the pathophysiological phenomena behind this relationship are unclear, and have been the object of intense research. Although our understanding of such mechanisms is slowly improving, much is still left to learn. With the recent advances in cancer biology, a diversity of biological pathways and novel targets and agents have been described in patients with haematological malignancies and successfully put into clinical practice. Clear examples are rituximab and brentuximab vedotin in patients with B cell lymphomas and Hodgkin lymphoma respectively. The main purpose of this review is not only to succinctly summarize what we know regarding the pathogenesis and pathophysiology of virally induced lymphomas and to describe the current practices in terms of diagnosis of treatment of such lymphomas, but also to provide a scientific rationale for the use of novel therapies that are likely to improve the outcomes of patients with these conditions.


Subject(s)
Herpesvirus 4, Human/isolation & purification , Human T-lymphotropic virus 1/isolation & purification , Lymphoma/therapy , Lymphoma/virology , Animals , Epstein-Barr Virus Infections/pathology , HTLV-I Infections/pathology , Humans
7.
Int J Cancer ; 134(12): 2961-71, 2014 Jun 15.
Article in English | MEDLINE | ID: mdl-24272143

ABSTRACT

Extracutaneous melanomas are poorly characterized tumors that include ocular (OM), mucosal (MM) and leptomeningeal melanomas, often lacking standardized staging and treatment guidelines. We analyzed cases of cutaneous melanoma (CM, N = 219,890), OM (N = 7,069) and MM (N = 2,755) of different anatomical origins, diagnosed between 1988 and 2010, recorded in the Surveillance Epidemiology and End Results (SEER) database. Relative survival was studied in patients grouped by summary stage classification (localized, regional or distant disease) and in multivariate models adjusting for varying distribution of baseline factors. Unlike in CM, the incidence rate in MM increased exponentially with age. Five-year relative survival was significantly worse for OM (78%) and for most mucosal sites (aggregate 34%, range 3-69%) compared with CM (89%). The differences between primary sites were particularly pronounced in localized disease, with a hazard ratio of 5.7 for OM, 4.3-9.0 for external genital or oral cavity MM and 19.8-90.4 for other mucosal locations. Melanomas of the pharynx, gastrointestinal, urinary tract and vagina had poor outcomes regardless of clinical stage. In contrast to CM, there was no evidence of improved survival in OM and MM during the study period. A substantial proportion of patients with operable OM or MM underwent radical organ resections (13-88% depending on site and stage) or perioperative radiotherapy (0-66%). In conclusion, extracutaneous melanomas have a markedly worse survival than CM and aggressive locoregional management appears to be insufficient for their control. Because of poor outcomes in MM, studies of systemic therapy are warranted regardless of the extent of disease at presentation.


Subject(s)
Eye Neoplasms/epidemiology , Melanoma/epidemiology , Meningeal Neoplasms/epidemiology , Adult , Aged , Aged, 80 and over , Databases, Factual/statistics & numerical data , Databases, Factual/trends , Eye Neoplasms/mortality , Eye Neoplasms/therapy , Female , Humans , Male , Melanoma/mortality , Melanoma/therapy , Meningeal Neoplasms/mortality , Meningeal Neoplasms/therapy , Middle Aged , Population Surveillance , SEER Program , Skin Neoplasms/epidemiology , Skin Neoplasms/mortality , Skin Neoplasms/therapy , Social Class , Survival , Young Adult , Melanoma, Cutaneous Malignant
12.
Cell Immunol ; 256(1-2): 86-91, 2009.
Article in English | MEDLINE | ID: mdl-19230866

ABSTRACT

Recent studies have implicated the cell surface receptor Programmed Death-1 (PD-1) in numerous models of T cell anergy, though the specific mechanisms by which the PD-1 signal maintains tolerance is not clear. We demonstrate that the depletion of PD-1 with siRNA results in a complete reversal of clonal anergy in the A.E7 T cell model, suggesting that the mechanism by which PD-1 maintains the anergic phenotype is a T-cell-intrinsic phenomenon, and not one dependent on other cell populations in vivo. We have also shown that the neutralization of IL-2 during restimulation abrogates the effect of PD-1 depletion, suggesting that tolerance mediated by PD-1 is wholly IL-2 dependent, and likewise intrinsic to the tolerized cells.


Subject(s)
Apoptosis Regulatory Proteins/antagonists & inhibitors , CD4-Positive T-Lymphocytes/immunology , Clonal Anergy/immunology , Animals , Antigens/administration & dosage , Antigens, Surface/genetics , Antigens, Surface/metabolism , Apoptosis Regulatory Proteins/genetics , Apoptosis Regulatory Proteins/metabolism , Base Sequence , CD4-Positive T-Lymphocytes/cytology , CD4-Positive T-Lymphocytes/metabolism , Cell Line , Cell Proliferation , Clonal Anergy/genetics , Columbidae , Cytochromes c/immunology , DNA Primers/genetics , Interleukin-2/antagonists & inhibitors , Interleukin-2/metabolism , Mice , Mice, Inbred BALB C , Phenotype , Programmed Cell Death 1 Receptor , RNA, Messenger/genetics , RNA, Messenger/metabolism , RNA, Small Interfering/genetics , Signal Transduction/immunology , Transfection , Transplantation Tolerance/genetics , Transplantation Tolerance/immunology
13.
J Anal Toxicol ; 32(5): 339-43, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18544218

ABSTRACT

We report that use of the popular analgesic tramadol can cause false-positive urine buprenorphine results. We examined the extent of tramadol cross-reactivity in three point-of-care urine buprenorphine immunoassays (ACON, QuikStrip, and ABMC) and an instrument-based one (Cedia). We tested 29 urine samples from patients known to be taking tramadol. Ten different samples tested positive for urine buprenorphine by at least one immunoassay. Samples with positive buprenorphine screens by immunoassay were tested for total buprenorphine and total norbuprenorphine content by liquid chromatography-tandem mass spectrometry (LC-MS-MS), which confirmed that seven of the 10 positive samples were false-positives. The remaining three positive immunoassay samples had insufficient quantity for LC-MS-MS testing. No false-positives were detected with the ACON (10 ng/mL calibration cutoff) or the Cedia assay (using a 20 ng/mL calibration cutoff). All four false-positive Cedia results (using a 5 ng/mL cutoff) in this study tested negative using the ACON device. Our data suggest that tramadol use can cause false-positive urine buprenorphine immunoassays, and this effect appears to be assay-dependent. Tramadol interference with the Cedia assay is clinically relevant, especially if the 5 ng/mL calibration cutoff is used.


Subject(s)
Analgesics, Opioid/therapeutic use , Buprenorphine/urine , Immunoassay/methods , Point-of-Care Systems , Tramadol/therapeutic use , Artifacts , Buprenorphine/immunology , Chromatography, High Pressure Liquid , Cross Reactions , False Positive Reactions , Humans , Predictive Value of Tests , Spectrometry, Mass, Electrospray Ionization , Tandem Mass Spectrometry
14.
J Immunol ; 177(11): 7820-32, 2006 Dec 01.
Article in English | MEDLINE | ID: mdl-17114453

ABSTRACT

Biobreeding (BB) rats model type 1 autoimmune diabetes (T1D). BB diabetes-prone (BBDP) rats develop T1D spontaneously. BB diabetes-resistant (BBDR) rats develop T1D after immunological perturbations that include regulatory T cell (Treg) depletion plus administration of low doses of a TLR ligand, polyinosinic-polycytidylic acid. Using both models, we analyzed CD4+CD25+ and CD4+CD45RC- candidate rat Treg populations. In BBDR and control Wistar Furth rats, CD25+ T cells comprised 5-8% of CD4+ T cells. In vitro, rat CD4+CD25+ T cells were hyporesponsive and suppressed T cell proliferation in the absence of TGF-beta and IL-10, suggesting that they are natural Tregs. In contrast, CD4+CD45RC(-) T cells proliferated in vitro in response to mitogen and were not suppressive. Adoptive transfer of purified CD4+CD25+ BBDR T cells to prediabetic BBDP rats prevented diabetes in 80% of recipients. Surprisingly, CD4+CD45RC-CD25- T cells were equally protective. Quantitative studies in an adoptive cotransfer model confirmed the protective capability of both cell populations, but the latter was less potent on a per cell basis. The disease-suppressing CD4+CD45RC-CD25- population expressed PD-1 but not Foxp3, which was confined to CD4+CD25+ cells. We conclude that CD4+CD25+ cells in the BBDR rat act in vitro and in vivo as natural Tregs. In addition, another population that is CD4+CD45RC-CD25- also participates in the regulation of autoimmune diabetes.


Subject(s)
Diabetes Mellitus, Type 1/metabolism , Forkhead Transcription Factors/biosynthesis , Interleukin-2 Receptor alpha Subunit/biosynthesis , T-Lymphocyte Subsets/metabolism , T-Lymphocytes, Regulatory/metabolism , Adoptive Transfer , Animals , Autoimmune Diseases/immunology , Autoimmune Diseases/metabolism , Cell Proliferation , Diabetes Mellitus, Type 1/immunology , Flow Cytometry , Leukocyte Common Antigens/biosynthesis , Protein Tyrosine Phosphatase, Non-Receptor Type 1 , Rats , Rats, Inbred BB , Reverse Transcriptase Polymerase Chain Reaction , T-Lymphocyte Subsets/immunology , T-Lymphocytes, Regulatory/immunology
15.
J Immunol ; 173(12): 7331-8, 2004 Dec 15.
Article in English | MEDLINE | ID: mdl-15585857

ABSTRACT

Ag-specific immune tolerance results from the induction of cellular mechanisms that limit T cell responses to selective Ags. One of these mechanisms is characterized by attenuated proliferation and decreased IL-2 production in fully stimulated CD4(+) Th cells and is denoted T cell anergy. We report the identification of the early growth response gene (Egr-2; Krox-20), a zinc-finger transcription factor, as a key protein required for induction of anergy in cultured T cells. Gene array screening revealed high Egr-2 expression distinctly persists in anergized but not proliferating murine A.E7 T cells. In contrast, Egr-1, a related family member induced upon costimulation, displays little or no expression in the anergic state. IL-2-mediated abrogation of anergy causes rapid depletion of Egr-2 protein. Full stimulation of anergic A.E7 T cells fails to enhance IL-2 and Egr-1 expression, whereas Egr-2 expression is greatly increased. Silencing Egr-2 gene expression by small interfering RNA treatment of cultured A.E7 T cells before incubation with anti-CD3 alone prevents full induction of anergy. However, small interfering RNA-mediated depletion of Egr-2 5 days after anergy induction does not appear to abrogate hyporesponsiveness to stimulation. These data indicate that sustained Egr-2 expression is necessary to induce a full anergic state through the actions of genes regulated by this transcription factor.


Subject(s)
CD4-Positive T-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/metabolism , Clonal Anergy/immunology , DNA-Binding Proteins/physiology , Lymphocyte Activation/immunology , Transcription Factors/physiology , Animals , CD28 Antigens/pharmacology , CD3 Complex/pharmacology , CD4-Positive T-Lymphocytes/enzymology , Cell Line , Cell Proliferation , Clone Cells , DNA-Binding Proteins/antagonists & inhibitors , DNA-Binding Proteins/biosynthesis , DNA-Binding Proteins/genetics , Early Growth Response Protein 2 , Extracellular Signal-Regulated MAP Kinases/metabolism , Gene Expression Regulation/immunology , Gene Silencing , Interleukin-2/biosynthesis , Interleukin-2/pharmacology , Lymphocyte Activation/genetics , Mice , Mice, Inbred C57BL , Phosphorylation , RNA, Small Interfering/pharmacology , Receptors, Antigen, T-Cell/physiology , Transcription Factors/antagonists & inhibitors , Transcription Factors/biosynthesis , Transcription Factors/genetics , Up-Regulation/immunology , Zinc Fingers/immunology
16.
J Biol Chem ; 278(46): 45397-405, 2003 Nov 14.
Article in English | MEDLINE | ID: mdl-12960166

ABSTRACT

Elucidating the mechanisms by which the transcription machinery accesses promoters in their chromatin environment is a fundamental aspect of understanding gene regulation. The phas promoter is normally constrained by a rotationally and translationally positioned nucleosome over its TATA region except during embryogenesis when it is potentiated by the presence of Phaseolus vulgaris ABI3-like factor (PvALF), a plant-specific transcription factor, and activated by an abscisic acid (ABA)-induced signal transduction cascade. Ectopic expression of PvALF and the supply of ABA in transgenic tobacco or Arabidopsis leaves can activate expression from phas. We confirmed by [3H]thymidine incorporation that active DNA replication occurred concomitant with the presence of PvALF and ABA. Arrest of DNA synthesis or S phase progression by infiltration of the leaves with replication inhibitors (hydroxyurea, roscovitine, mimosine) strongly inhibited transcriptional activation, especially the ABA-mediated activation step. Similarly, activation of endogenous Arabidopsis MAT and LEA genes in leaf tissue by the presence of ABA and ectopically expressed PvALF was inhibited by DNA replication arrest. No change in transcript levels on the arrest of replication was detected for abi1, abi2, and era1, negative regulators of the ABA signal transduction cascade or for cell cycle components ick1 and aip3. However, a reduction in transcript accumulation for the crucial ABA signaling effector, abi5, occurred upon DNA replication arrest (probably reflected in the decrease in MAT and LEA gene expression). Contrary to the conventional view that ABA inhibits DNA replication, our findings show that ABA acts in concert with S phase progression to activate gene expression.


Subject(s)
Plant Proteins/genetics , S Phase , Transcriptional Activation , Arabidopsis/metabolism , Chromatin/metabolism , DNA/metabolism , Gene Expression Regulation , Gene Expression Regulation, Plant , Hydroxyurea/pharmacology , Nucleosomes/metabolism , Phaseolus/metabolism , Plants, Genetically Modified , Plasmids/metabolism , Promoter Regions, Genetic , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Ribonucleases/metabolism , Signal Transduction , Time Factors , Nicotiana
17.
Plant J ; 33(5): 853-66, 2003 Mar.
Article in English | MEDLINE | ID: mdl-12609027

ABSTRACT

The phas promoter displays stringent spatial regulation, being very highly expressed during embryogenesis and completely silent during all phases of vegetative development in bean, Phaseolus vulgaris. This pattern is maintained in transgenic tobacco and, as shown here, Arabidopsis. Dimethyl sulphate in vivo footprinting analyses revealed that over 20 cis-elements within the proximal 295 bp of the phas promoter are protected by factor binding in seed tissues whereas none are bound in leaves. The hypothesis that this complex profile represents a summation of several module (cotyledon, hypocotyl, and radicle)-specific factor-DNA interactions has been explored by the incorporation of site-directed substitution mutations into 10 locations within the -295phas promoter. Only 2.6% of -295phas promoter activity remained after mutation of the G-box; the CCAAAT box, the E-box and the RY elements were also found to mediate high levels of expression in embryos. Whereas the CACA element has dual positive and negative regulatory roles, the vicilin box was identified as a strong negative regulatory element. The proximal (-70 to -64) RY motif was found to bestow expression in the hypocotyl while all the RY elements contribute to expression in cotyledons but not to vascular tissue expression during embryogenesis. RY elements at positions -277 to -271, -260 to -254, and -237 to -231 were found to orchestrate radicle-specific repression. The G-box appears to be the functional abscisic acid responsive element and the E-site may be a coupling element. The results substantiate the concept that autarkical cis-element functions generate modular patterning during embryogenesis. They also reflect the existence of both redundancy and hierarchy in cis-element interactions. Importantly, the virtually identical expression patterns observed for the two distantly related plants studied argue strongly for the generality of function for the observed factor-element interactions.


Subject(s)
Arabidopsis/embryology , Arabidopsis/genetics , Gene Expression Regulation, Developmental , Gene Expression Regulation, Plant , Phaseolus/genetics , Plant Proteins/genetics , Promoter Regions, Genetic/genetics , Genes, Reporter/genetics , Mutation , Plants, Genetically Modified , Regulatory Sequences, Ribonucleic Acid/genetics , Response Elements/genetics , Seeds/embryology , Seeds/genetics , Nicotiana/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...